Drug Development, Treatment, Artificial Intelligence, Molecule Engineering and Innovation
Platform
Pipeline
About
News
Contact
News
BioSpace Says Verseon Is "Changing the Paradigm of Drug Discovery"
“What sets Verseon apart is its use of molecular physics modeling to enable the atomic-level engineering of new molecules.”
MAY 03, 2022
Why AI Alone Cannot Find Tomorrow’s Medicines
“AI is good at interpolating features within the bounds of a well-explored pool of training data but unable to make useful extrapolations far outside it."
April 27, 2022
Impact Wealth Magazine Hails Verseon as the Company Redefining Delay, Prevention, and Treatment of Disease
"Between its regulated pharmaceuticals and consumer healthspan products, Verseon ... will likely transform twenty-first century medicine and touch the lives of everyone on the planet."
April 11, 2022
Verseon’s Kevin Short Speaks with Pharmaceutical Technology Magazine About the Utility of Data and AI in Medicinal Chemistry
“As we collect much larger and more complex data sets from increasingly advanced functionally predictive assays, machine-learning tools could potentially make medicinal chemistry operations more efficient.”
April 2, 2022
MarkTechPost Features Verseon in Latest Issue of AI in Healthcare Magazine
Interview with Verseon CEO Adityo covers challenges in small-molecule drug discovery and what Verseon is doing to address them, spanning advances in fundamental science and AI.
March 30, 2022
Dr. Sangtae Kim to Lead Verseon’s New AI and Data-Science Initiative as CTO
Accomplished veteran of pharmaceutical industry and academia joins Verseon's senior executive team
January 12, 2022
Verseon's Anirban Datta Explains Challenges for Current Antiviral Drugs and Vaccines
Company suggests focusing on host-centric approach for a new class of antivirals as a lasting solution to combat SARS-CoV-2 and other viruses
January 11, 2022
Verseon's Unique Physics- & AI-based Platform Highlighted in Nano Magazine Feature on the Future of Drug Discovery
Comprehensive drug design & development platform praised for its ability to systematically generate multiple chemically distinct candidates in each program
December 15, 2021
Verseon Nominates Primary Drug Candidate for Oral Prophylactic Treatment of the Most Common Cause of Diabetic Vision Loss
Precision-engineered by Verseon's unique computational platform, VE-4840 advances as primary development candidate after key in vivo and preliminary toxicology studies
August 5, 2021
Verseon's Diabetic Retinopathy Drug Candidate Hits Key Milestone, Demonstrating Significant Reduction of Retinal Vascular Permeability
An in vivo efficacy study strongly suggests that drug candidate VE-4840 mitigates damage to retinal blood vessels—a milestone in establishing the compound’s effectiveness as an oral treatment of diabetic retinopathy
May 5, 2021
Verseon's Patent Portfolio Continues to Grow as Platform Produces New Family of Novel Potential Drugs
Receipt of European patent for innovative thrombin inhibitors underscores the power of Verseon's systematic drug design technologies
January 12, 2021
Wellcome and Allergan Veteran Trevor M. Jones Joins Verseon’s Scientific Advisory Board
New addition to company's advisors brings extensive drug research and development experience to the role
November 30, 2020
Verseon Announces Program Targeting Aggressive Metastatic Cancer
The company's third cancer program targets an overexpressed protease on the surface of many solid-tumor cancer cells
September 30, 2020
Journal Thrombosis Research Publishes Peer Reviewed Results Demonstrating Efficacy and Reduced Bleeding Risk for Verseon Anticoagulant VE-1902
New class of anticoagulant drug candidates demonstrates a unique combination of efficacy with lower bleeding in preclinical testing
April 20, 2020
Dean of Harvard School of Engineering Joins Verseon's Scientific Advisory Board
Frank Doyle, Dean of Harvard’s School of Engineering and Applied Sciences, brings fresh perspective to complement Verseon's team of advisors
February 24, 2020